Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Sorafenib|DRUG: Letrozole
Sponsor: Rutgers, The State University of New Jersey
Collaborators: Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI)|Bayer|Novartis Pharmaceuticals